{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/108128"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/108128","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Immunotherapy for murine glioma","abstract":"Oncolytic viral immunotherapy is a novel approach to cancer treatment. Viruses can directly kill cancer cells, provide antigens to dendritic cells to stimulate a T cell response, and make cancer cells express genes of immune-enhancing cytokines locally within the tumor microenvironment. We hypothesized that the combination of oncolytic virus with a local stimulus for activating tumor-specific T cells and an anti-immunosuppressant would improve treatment of gliomas. An oncolytic virus encoding IL15Ra-IL15 (the T cell activating stimulus) and the prostaglandin synthesis inhibitor celecoxib (the anti-immunosuppressant) were combined with adoptive transfer of tumor-specific T cells. Two oncolytic poxviruses, vvDD vaccinia virus and myxoma virus, were each engineered to express the fusion protein IL15Ra-IL15 and a fluorescent protein (YFP or tdTomato Red). Viral gene expression (YFP or tdTomato Red) was confirmed in the murine glioma line GL261 in vitro and in vivo. Orthotopic GL261 tumors in immunocompetent C57BL/6J mice were treated with vvDD-IL15Ra-YFP vaccinia virus or vMyx-IL15Ra-tdTr combined with other treatments, including vaccination with GARC-1 peptide (a neoantigen for GL261), rapamycin, celecoxib, and adoptive T cell therapy. We found that vvDD-IL15Ra-YFP and vMyx-IL15Ra-tdTr each infected and killed GL261 cells in vitro. In vivo, NK cells and CD8+ T cells were increased in the tumor due to the expression of IL15Ra-IL15. Each component of a combination treatment contributed to prolonging survival: an oncolytic virus, the IL15Ra-IL15 expressed by the virus, a source of T cells (whether by pre-vaccination or adoptive transfer), and prostaglandin inhibition all synergized to produce total elimination of gliomas in a majority of mice gliomas. vvDD-IL15Ra-YFP occasionally caused ventriculitis-meningitis, but vMyx-IL15Ra-tdTr was safe and effective, causing a strong infiltration of tumor-specific T cells and eliminating gliomas in 83% of treated mice. All these facts suggest that IL15Ra-IL15-armed oncolytic poxviruses provide potent antitumor effects against brain tumors when combined with adoptive T cell therapy, rapamycin and celecoxib and that this combination treatment might be a promising method for human glioma therapy.","abstract_html":"Oncolytic viral immunotherapy is a novel approach to cancer treatment. Viruses can directly kill cancer cells, provide antigens to dendritic cells to stimulate a T cell response, and make cancer cells express genes of immune-enhancing cytokines locally within the tumor microenvironment. We hypothesized that the combination of oncolytic virus with a local stimulus for activating tumor-specific T cells and an anti-immunosuppressant would improve treatment of gliomas. An oncolytic virus encoding IL15Ra-IL15 (the T cell activating stimulus) and the prostaglandin synthesis inhibitor celecoxib (the anti-immunosuppressant) were combined with adoptive transfer of tumor-specific T cells. Two oncolytic poxviruses, vvDD vaccinia virus and myxoma virus, were each engineered to express the fusion protein IL15Ra-IL15 and a fluorescent protein (YFP or tdTomato Red). Viral gene expression (YFP or tdTomato Red) was confirmed in the murine glioma line GL261 in vitro and in vivo. Orthotopic GL261 tumors in immunocompetent C57BL/6J mice were treated with vvDD-IL15Ra-YFP vaccinia virus or vMyx-IL15Ra-tdTr combined with other treatments, including vaccination with GARC-1 peptide (a neoantigen for GL261), rapamycin, celecoxib, and adoptive T cell therapy. We found that vvDD-IL15Ra-YFP and vMyx-IL15Ra-tdTr each infected and killed GL261 cells in vitro. In vivo, NK cells and CD8+ T cells were increased in the tumor due to the expression of IL15Ra-IL15. Each component of a combination treatment contributed to prolonging survival: an oncolytic virus, the IL15Ra-IL15 expressed by the virus, a source of T cells (whether by pre-vaccination or adoptive transfer), and prostaglandin inhibition all synergized to produce total elimination of gliomas in a majority of mice gliomas. vvDD-IL15Ra-YFP occasionally caused ventriculitis-meningitis, but vMyx-IL15Ra-tdTr was safe and effective, causing a strong infiltration of tumor-specific T cells and eliminating gliomas in 83% of treated mice. All these facts suggest that IL15Ra-IL15-armed oncolytic poxviruses provide potent antitumor effects against brain tumors when combined with adoptive T cell therapy, rapamycin and celecoxib and that this combination treatment might be a promising method for human glioma therapy.","abstract_has_math":false,"creators":["Tang, Bingtao"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Molecular & Integrative Physi","degree_department":null,"school":null,"contributors":["Roy, Edward","Shisler, Joanna","Lichtor, Terence","Raetzman, Lori","Nelson, Erik"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-08-26T23:57:17Z","date_published":"2020-08-26T23:57:17Z","updated_at":"2026-07-22T22:24:47Z","subjects":["Glioma","Immunotherapy","Oncolytic Virus, vvDD Vaccinia","Myxoma","IL15","Rapamycin","Celecoxib","Adoptive Cell Therapy","Surgical Resection","Overcoming Immunosuppression","Prolonged Survival"],"languages":["en"],"rights":["Copyright 2020 Bingtao Tang"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/108128","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Roy, Edward","Shisler, Joanna","Lichtor, Terence","Raetzman, Lori","Nelson, Erik"]},{"key":"dc:creator","label":"Author","values":["Tang, Bingtao"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2020-08-26T23:57:17Z","2022-08-26T23:58:55Z","2020-04-27","2020-05"]},{"key":"dc:type","label":"Dc Type","values":["text","Thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Molecular & Integrative Physi"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Glioma","Immunotherapy","Oncolytic Virus, vvDD Vaccinia","Myxoma","IL15","Rapamycin","Celecoxib","Adoptive Cell Therapy","Surgical Resection","Overcoming Immunosuppression","Prolonged Survival"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2020 Bingtao Tang"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/108128"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Oncolytic viral immunotherapy is a novel approach to cancer treatment. Viruses can directly kill cancer cells, provide antigens to dendritic cells to stimulate a T cell response, and make cancer cells express genes of immune-enhancing cytokines locally within the tumor microenvironment. We hypothesized that the combination of oncolytic virus with a local stimulus for activating tumor-specific T cells and an anti-immunosuppressant would improve treatment of gliomas. An oncolytic virus encoding IL15Ra-IL15 (the T cell activating stimulus) and the prostaglandin synthesis inhibitor celecoxib (the anti-immunosuppressant) were combined with adoptive transfer of tumor-specific T cells. Two oncolytic poxviruses, vvDD vaccinia virus and myxoma virus, were each engineered to express the fusion protein IL15Ra-IL15 and a fluorescent protein (YFP or tdTomato Red). Viral gene expression (YFP or tdTomato Red) was confirmed in the murine glioma line GL261 in vitro and in vivo. Orthotopic GL261 tumors in immunocompetent C57BL/6J mice were treated with vvDD-IL15Ra-YFP vaccinia virus or vMyx-IL15Ra-tdTr combined with other treatments, including vaccination with GARC-1 peptide (a neoantigen for GL261), rapamycin, celecoxib, and adoptive T cell therapy. We found that vvDD-IL15Ra-YFP and vMyx-IL15Ra-tdTr each infected and killed GL261 cells in vitro. In vivo, NK cells and CD8+ T cells were increased in the tumor due to the expression of IL15Ra-IL15. Each component of a combination treatment contributed to prolonging survival: an oncolytic virus, the IL15Ra-IL15 expressed by the virus, a source of T cells (whether by pre-vaccination or adoptive transfer), and prostaglandin inhibition all synergized to produce total elimination of gliomas in a majority of mice gliomas. vvDD-IL15Ra-YFP occasionally caused ventriculitis-meningitis, but vMyx-IL15Ra-tdTr was safe and effective, causing a strong infiltration of tumor-specific T cells and eliminating gliomas in 83% of treated mice. All these facts suggest that IL15Ra-IL15-armed oncolytic poxviruses provide potent antitumor effects against brain tumors when combined with adoptive T cell therapy, rapamycin and celecoxib and that this combination treatment might be a promising method for human glioma therapy.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2022-05-01","The student, Bingtao Tang, accepted the attached license on 2020-04-25 at 20:12.","The student, Bingtao Tang, submitted this Dissertation for approval on 2020-04-25 at 20:44.","This Dissertation was approved for publication on 2020-04-27 at 13:15.","DSpace SAF Submission Ingestion Package generated from Vireo submission #15074 on 2020-08-25 at 17:28:15","Made available in DSpace on 2020-08-26T23:57:17Z (GMT). No. of bitstreams: 3 TANG-DISSERTATION-2020.pdf: 2165662 bytes, checksum: ad32ed030fc2bbfeeee427b7be22d558 (MD5) LICENSE.txt: 4209 bytes, checksum: 5904cad9f4004e1697d9048e83c81372 (MD5) PROQUEST_LICENSE.txt: 4555 bytes, checksum: 8094b74b35cb927b372010f52e5d7a39 (MD5) Previous issue date: 2020-04-27","Embargo set by: Seth Robbins for item 115740 Lift date: 2022-08-26T23:57:28Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 115740 Lift date: 2022-08-26T23:58:55Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Immunotherapy for murine glioma"]}]}],"canonical_facts":{"dc:contributor":["Roy, Edward","Shisler, Joanna","Lichtor, Terence","Raetzman, Lori","Nelson, Erik"],"dc:creator":["Tang, Bingtao"],"dc:date":["2020-08-26T23:57:17Z","2022-08-26T23:58:55Z","2020-04-27","2020-05"],"dc:description":["Oncolytic viral immunotherapy is a novel approach to cancer treatment. Viruses can directly kill cancer cells, provide antigens to dendritic cells to stimulate a T cell response, and make cancer cells express genes of immune-enhancing cytokines locally within the tumor microenvironment. We hypothesized that the combination of oncolytic virus with a local stimulus for activating tumor-specific T cells and an anti-immunosuppressant would improve treatment of gliomas. An oncolytic virus encoding IL15Ra-IL15 (the T cell activating stimulus) and the prostaglandin synthesis inhibitor celecoxib (the anti-immunosuppressant) were combined with adoptive transfer of tumor-specific T cells. Two oncolytic poxviruses, vvDD vaccinia virus and myxoma virus, were each engineered to express the fusion protein IL15Ra-IL15 and a fluorescent protein (YFP or tdTomato Red). Viral gene expression (YFP or tdTomato Red) was confirmed in the murine glioma line GL261 in vitro and in vivo. Orthotopic GL261 tumors in immunocompetent C57BL/6J mice were treated with vvDD-IL15Ra-YFP vaccinia virus or vMyx-IL15Ra-tdTr combined with other treatments, including vaccination with GARC-1 peptide (a neoantigen for GL261), rapamycin, celecoxib, and adoptive T cell therapy. We found that vvDD-IL15Ra-YFP and vMyx-IL15Ra-tdTr each infected and killed GL261 cells in vitro. In vivo, NK cells and CD8+ T cells were increased in the tumor due to the expression of IL15Ra-IL15. Each component of a combination treatment contributed to prolonging survival: an oncolytic virus, the IL15Ra-IL15 expressed by the virus, a source of T cells (whether by pre-vaccination or adoptive transfer), and prostaglandin inhibition all synergized to produce total elimination of gliomas in a majority of mice gliomas. vvDD-IL15Ra-YFP occasionally caused ventriculitis-meningitis, but vMyx-IL15Ra-tdTr was safe and effective, causing a strong infiltration of tumor-specific T cells and eliminating gliomas in 83% of treated mice. All these facts suggest that IL15Ra-IL15-armed oncolytic poxviruses provide potent antitumor effects against brain tumors when combined with adoptive T cell therapy, rapamycin and celecoxib and that this combination treatment might be a promising method for human glioma therapy.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2022-05-01","The student, Bingtao Tang, accepted the attached license on 2020-04-25 at 20:12.","The student, Bingtao Tang, submitted this Dissertation for approval on 2020-04-25 at 20:44.","This Dissertation was approved for publication on 2020-04-27 at 13:15.","DSpace SAF Submission Ingestion Package generated from Vireo submission #15074 on 2020-08-25 at 17:28:15","Made available in DSpace on 2020-08-26T23:57:17Z (GMT). No. of bitstreams: 3 TANG-DISSERTATION-2020.pdf: 2165662 bytes, checksum: ad32ed030fc2bbfeeee427b7be22d558 (MD5) LICENSE.txt: 4209 bytes, checksum: 5904cad9f4004e1697d9048e83c81372 (MD5) PROQUEST_LICENSE.txt: 4555 bytes, checksum: 8094b74b35cb927b372010f52e5d7a39 (MD5) Previous issue date: 2020-04-27","Embargo set by: Seth Robbins for item 115740 Lift date: 2022-08-26T23:57:28Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 115740 Lift date: 2022-08-26T23:58:55Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only"],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/108128"],"dc:language":["en"],"dc:rights":["Copyright 2020 Bingtao Tang"],"dc:subject":["Glioma","Immunotherapy","Oncolytic Virus, vvDD Vaccinia","Myxoma","IL15","Rapamycin","Celecoxib","Adoptive Cell Therapy","Surgical Resection","Overcoming Immunosuppression","Prolonged Survival"],"dc:title":["Immunotherapy for murine glioma"],"dc:type":["text","Thesis"],"thesis:degree_discipline":["Molecular & Integrative Physi"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:47Z"}